A new hypothesis and theory article published in Frontiers in Integrative Neuroscience by Boris Živný of the NeuroCentrum Clinic and SPP Institute in Jesenice, Czechia, proposes a contemporary answer. The paper introduces Persistent Afferent Bias, or PAB, a state-dependent alteration in sensory weighting through which somatic disruption is proposed to influence autonomic regulation. Rather than treating facilitation as a property of a single hyperexcitable segment, Živný reframes it as a network-level phenomenon: neurons remain structurally and functionally intact, but particular afferent streams exert a disproportionate influence on system behavior, altering neural gain, reflex responsiveness, and autonomic output. The construct is positioned as the previously unarticulated neurophysiological mechanism linking altered somatic input to changes in regulatory state within the author’s broader Somato-Psychic Pathway model.

The theoretical foundation rests on a growing recognition in contemporary neuroscience that bias is not merely a byproduct of imperfect processing but a fundamental property of neural systems. Recent evidence indicates that such biases are associated with identifiable neural signatures and organized patterns of processing rather than random distortions, while attentional bias itself appears dynamically regulated and context-dependent. Within this framework, alterations in sensorimotor processing are conceptualized as state-dependent changes in the relative weighting of afferent input within distributed neural networks. Persistent Afferent Bias may arise from multiple sources, including nociceptive input, muscle spindle activity, fascial mechanoreceptor signaling, and viscerosomatic convergence, none of which require localized structural pathology.

Central to the argument is the principle of state-dependent neural regulation. Neuronal responsiveness is shaped not only by structural connectivity but by the system’s current physiological state, reflecting a dynamic integration of autonomic tone, neuromodulatory activity, metabolic and inflammatory signals, and descending regulatory influences. Contemporary predictive processing models, notably those developed by Karl Friston and by Lisa Feldman Barrett and W. Kyle Simmons, describe sensory processing as an actively regulated, predictive process in which the nervous system continuously integrates afferent input with prior expectations to optimize adaptive responses. As a consequence, identical sensory inputs may produce markedly different physiological and behavioral outputs depending on the system’s regulatory state, providing a mechanistic explanation for clinical observations such as variability in tenderness, context-dependent reflex responses, and the rapid reversibility of somatic findings.

Recent empirical work lends support to this broader principle. Studies published in 2025 and 2026 demonstrate that persistent nociceptive input can bias attentional and perceptual processing, leading to preferential weighting of pain-related information, and that attentional bias is dynamically regulated rather than passively distorted. Other findings suggest that perceptual and decision-related representations are continuously shaped by prior states, with past activity reactivated and interacting with ongoing processing in a temporally structured manner, while certain forms of bias may reflect more stable organizational tendencies, such as preferential allocation of processing resources toward self-relevant information. Taken together, these observations suggest that bias is neither a fixed defect nor a transient disturbance but an emergent property of neural systems that is both dynamically regulated and structurally constrained.

Živný organizes the model around a hierarchical regulatory cascade comprising three functionally distinct but related levels. Distorted Proprioceptive Information, or DPI, refers to an alteration in the quality of incoming sensory input, typically arising from disturbances within the somatic system, and represents only one of several potential contributors to Persistent Afferent Bias, alongside persistent nociceptive input, altered muscle spindle activity, visceral afferent signaling, and changes in interoceptive processing. PAB itself represents a state-dependent reorganization of sensory weighting within neural networks. Somato-Psychic Autonomic Dysregulation, or SPAD, reflects a more stable alteration in autonomic regulation that emerges when biased processing becomes functionally embedded within the organism’s regulatory state. Under sustained conditions, SPAD may subsequently give rise to broader functional manifestations, including Somato-Psychic Syndrome, or SPS, a clinical phenotype characterized by emotional, behavioral, cognitive, developmental, and regulatory features such as sleep dysregulation, emotional lability, anxiety features, and attentional instability.

The framework is explicitly positioned as complementary to, rather than competing with, several established bodies of theory. Models of sensorimotor integration and fusimotor control show that muscle spindle sensitivity is dynamically regulated through interactions between alpha and gamma motor systems, supporting the principle that afferent weighting is state-dependent, though these models focus on posture and movement rather than autonomic embedding. Classical somato-autonomic reflex physiology, documented experimentally since the work of Akio Sato and R. F. Schmidt in 1987, demonstrates that somatic stimulation can influence cardiovascular and gastrointestinal function through spinal, brainstem, and supraspinal pathways; PAB extends this perspective by proposing that repeated or sustained afferent influences become progressively incorporated into longer-term regulatory configurations rather than producing only transient responses.

Pain science contributes the concepts of central sensitization and nociplastic pain, which describe increased responsiveness within central nociceptive pathways that can persist beyond immediate tissue injury. The PAB framework builds on these insights but broadens the scope considerably: whereas central sensitization primarily concerns nociceptive systems, Persistent Afferent Bias incorporates proprioceptive, interoceptive, and other afferent channels. Notably, the model emphasizes persistent low-grade and subthreshold nociceptive input that may never reach conscious awareness yet continues to influence autonomic regulation, neural gain, and state-dependent processing over extended periods, since the absence of pain does not imply the absence of ongoing nociceptive signaling. The Neurovisceral Integration model of Julian Thayer and colleagues, which links autonomic flexibility measured through heart rate variability to attention, emotion regulation, and executive function, is likewise treated as complementary, with PAB focusing on the afferent conditions that may give rise to altered autonomic states rather than on their downstream consequences.

Predictive processing and interoceptive inference models, including work by Anil Seth and Friston on active interoceptive inference, describe how neural systems generate and update representations of bodily and environmental states. PAB addresses an earlier stage of the same architecture, examining how sustained alterations in afferent input shape the informational landscape upon which predictive interpretations are constructed. Similarly, the concepts of allostasis and allostatic load, developed by Bruce McEwen and Peter Sterling, explain how organisms adapt to prolonged regulatory demands and how such adaptations can become maladaptive; PAB is proposed as one specific pathway contributing to the regulatory demands that allostatic mechanisms must manage, with persistence as its defining characteristic. The author suggests these adaptations are state-dependent and potentially reversible, persisting only as long as the primary source of afferent bias remains active.

The clinical implications are substantial and, the author argues, directly testable. The model predicts that targeted modification of somatic drivers should produce measurable changes in autonomic markers such as heart rate variability, pupillary dynamics, baroreflex sensitivity, and respiratory variability, even without direct central interventions. It further predicts a characteristic temporal sequence in which changes in autonomic regulation precede observable changes in emotional, behavioral, cognitive, or developmental domains, consistent with the principle of Directional Developmental Sequencing. The framework would be weakened if autonomic changes consistently failed to precede higher-order functional changes, or if modification of presumed somatic drivers showed no relationship to autonomic regulation. The concept emerged from clinical observations in pediatric and adolescent patients treated for Somato-Psychic Syndrome, in whom addressing clinically diagnosable axial somatic disruptions of the postural system was repeatedly followed by changes across higher regulatory domains within clinically relevant time frames. The author acknowledges significant limitations: the Somato-Psychic Pathway is a conceptual framework grounded in established neurophysiological principles rather than a definitive explanatory model, and the proposed relationships linking somatic disruption, PAB, SPAD, and SPS remain to be systematically investigated in longitudinal and experimental settings. The model is explicitly not intended to explain all forms of psychopathology, since genetic, neurodevelopmental, inflammatory, environmental, and psychosocial pathways remain fully compatible and independent. Future research, the paper concludes, will be necessary to determine the prevalence, boundary conditions, physiological signatures, and clinical relevance of Persistent Afferent Bias within broader models of autonomic regulation, neurodevelopment, and mental health.

Subject of Research: A theoretical neuroscience model linking persistent altered afferent input to autonomic dysregulation and higher-order functional manifestations

Article Title: Persistent Afferent Bias: a mechanistic link between somatic disruption and autonomic dysregulation

Article References: Živný, B. (2026). Persistent Afferent Bias: a mechanistic link between somatic disruption and autonomic dysregulation. Frontiers in Integrative Neuroscience, 20, Article 1848233. https://doi.org/10.3389/fnint.2026.1848233

Image Credits: AI Generated

DOI: 10.3389/fnint.2026.1848233

Keywords: Persistent Afferent Bias, autonomic dysregulation, somatic disruption, Somato-Psychic Pathway, central sensitization, predictive processing, allostatic load, proprioception, interoception, heart rate variability, neural gain, facilitated spinal segment

The review, led by Alexandra Elena Lazar and colleagues at George Emil Palade University of Medicine, Pharmacy, Science and Technology in Targu Mures, Romania, synthesizes 27 studies identified through a structured PubMed search covering June 2021 to June 2026. The authors conclude that rebound pain is not a single biological event but the product of an interaction between physiological nociceptive processes and modifiable perioperative management factors. In other words, how clinicians manage the transition from regional to systemic analgesia may matter as much as the biology of the block itself.

Defining the phenomenon has proven surprisingly difficult. Most researchers agree that rebound pain involves a clinically relevant increase in pain intensity following the resolution of a previously effective peripheral nerve block, but studies disagree on how to measure it. Some trials use an absolute threshold, such as a Numeric Rating Scale or Visual Analogue Scale score of 7 or higher after the block resolves. Others track the change in pain from the blocked state to the unblocked state, capturing escalations that may never cross a severe-pain cutoff. A composite Modified Rebound Pain Score has been proposed but never externally validated. Because the yardsticks differ, the reported incidence ranges wildly, and direct comparisons between trials are fraught.

The numbers, however, are striking enough to demand attention. After shoulder surgery under a single-shot interscalene block—the highest-risk scenario identified in the review—between roughly one-third and more than 80 percent of patients in control groups experienced rebound pain across randomized trials. Preventive strategies such as intravenous or perineural dexamethasone and multimodal periarticular injections reduced that figure to approximately 20 to 40 percent in several studies. In wrist and hand surgery under supraclavicular block, one trial reported rebound pain in 79 percent of control patients versus 32 percent of those given intravenous dexamethasone. Hip fracture surgery with a liposomal bupivacaine PENG block showed rates of 10 percent versus 43.3 percent with saline. Knee surgery results were less consistent: prolonging block duration alone after unicompartmental knee arthroplasty did not prevent rebound pain and was even associated with higher rebound pain scores in one study.

What explains the phenomenon? The best-supported mechanism is what the authors call the unmasking phenomenon. A peripheral nerve block silences afferent sensory transmission, but it does nothing to stop the surgical injury itself. Inflammation proceeds, peripheral nociceptors become sensitized by prostaglandins, bradykinin, histamine, and cytokines, and nociceptive input continues to build at the surgical site—all while the patient feels nothing. When local anesthetic concentrations decline and neural conduction recovers, the central nervous system is suddenly re-exposed to an inflamed tissue environment with heightened nociceptor excitability. The pain that arrives is not new; it has been accumulating behind a pharmacological curtain.

Central sensitization—the activity-dependent increase in excitability of neurons within central pain pathways—has been proposed as an alternative driver, but the review finds the evidence wanting. The abrupt onset and typically transient course of rebound pain fit poorly with a sustained centrally mediated hyperalgesic state. The authors position central sensitization as a potential amplifying factor rather than the primary mechanism. Preclinical work adds a further wrinkle: in rats, 0.5 percent ropivacaine sciatic nerve block produced transient heat hyperalgesia as mechanical analgesia resolved, raising the possibility that local anesthetics themselves contribute a hyperalgesic component. That modality-specific animal finding cannot establish clinical causation, but the review argues it should not be dismissed.

Beyond biology, the review highlights a concept it calls the transitional analgesic gap: the interval between loss of regional analgesia and the establishment of effective systemic pain control. This gap is shaped by block duration, the postoperative pain trajectory, the timing of rescue analgesia, and patient expectations—and it is especially dangerous when block resolution occurs after discharge, when no clinician is present to intervene. The gap is a contributor to, not a synonym for, rebound pain, but it is the piece of the puzzle that clinicians can most directly manipulate.

Who is most at risk? The principal multivariable evidence comes from a cohort study by Barry and colleagues, which found that surgery involving bone rather than soft tissue, absence of perioperative intravenous dexamethasone, younger age, and female sex were independently associated with rebound pain. A randomized trial by Touil and colleagues identified severe preoperative pain and high pain catastrophizing as secondary predictive factors, though these exploratory associations require confirmation. The review is careful to note that surgical procedure should be considered a risk marker rather than an independently established causal factor, since comparisons across procedures are confounded by block technique, analgesic protocols, and outcome definitions.

On prevention, the picture is encouraging but uneven. Scheduled multimodal analgesia—acetaminophen, NSAIDs or COX-2 inhibitors, and rescue opioids when indicated—should be initiated while the block is still working, rather than waiting for pain to return. Continuous peripheral nerve catheters and prolonged regional techniques have generally attenuated rebound pain, with continuous infraclavicular blockade reducing early rebound pain after distal radius fixation. Dexamethasone is the most extensively investigated adjuvant, and meta-analytic evidence supports an overall reduction in rebound-pain incidence after single-injection blocks, though individual trials have reported no benefit or even increased incidence despite prolonged block duration. Notably, opioid-based prevention failed: pre-emptive oral hydromorphone did not reduce rebound pain severity, pain trajectory, or opioid consumption after shoulder arthroscopy. A single anti-hyperalgesic dose of intravenous ketamine likewise failed to reduce severe rebound pain in ambulatory upper-limb surgery, and intravenous esketamine showed no benefit after interscalene block, though it did help after thoracic paravertebral block.

The review’s practical message is that no single intervention is uniformly effective, and management should remain procedure-specific and individualized. For hospitalized patients, the transition can be supervised with scheduled multimodal analgesia, timely rescue medication, and regular pain assessment during block resolution. For ambulatory patients, who frequently lose their blocks at home, clear verbal and written instructions about the expected duration of the block, the anticipated return of sensation, and the importance of starting scheduled analgesics before the block wears off are essential. The authors call for a consensus definition developed through formal methods such as a Delphi process, a core outcome set combining pain intensity, analgesic consumption, sleep quality, and functional recovery, and adequately powered procedure-specific trials with standardized background analgesia. Until then, rebound pain remains a reminder that the end of a nerve block is not the end of the anesthetic plan—it is the moment the plan matters most.

Subject of Research: Rebound pain following peripheral nerve block resolution in orthopedic surgery

Article Title: Rebound pain after regional anesthesia in orthopedic surgery: current evidence and clinical implications – a narrative review

Article References: Lazar, A. E., Frandeș, O., Gherghinescu, M. C., & Azamfirei, L. (2026). Rebound pain after regional anesthesia in orthopedic surgery: current evidence and clinical implications – a narrative review. Frontiers in Medicine, 13, Article 1930868. https://doi.org/10.3389/fmed.2026.1930868

Image Credits: AI Generated

DOI: 10.3389/fmed.2026.1930868

Keywords: rebound pain, regional anesthesia, peripheral nerve block, orthopedic surgery, multimodal analgesia, dexamethasone, central sensitization, transitional analgesic gap, postoperative pain, anesthesiology, opioid sparing, nerve block resolution

Medication overuse headache, or MOH, is one of the most burdensome complications of the world’s most disabling neurological conditions. Migraine affects roughly 1.1 billion people and ranks second globally among causes of years lived with disability. Most patients experience it episodically, but in a subset the attacks grow more frequent until the headache-free baseline erodes entirely. Under the International Classification of Headache Disorders, third edition, MOH is diagnosed when a person with a pre-existing primary headache develops headache on 15 or more days per month while overusing acute medications, triptans, ergots, opioids or combination analgesics on 10 or more days per month, or simple analgesics on 15 or more days per month, for more than three months. It affects roughly 1 to 2.5 percent of adults in the general population, but accounts for 30 to 50 percent of patients presenting with chronic daily headache at specialized centers, and women are affected three to four times more often than men.

Sleep complaints are nearly universal in this population. In cohorts of MOH patients assessed with validated insomnia instruments, prevalence ranges from roughly 38 to 60 percent, and comorbid depression or anxiety is present in approximately 40 to 50 percent of cases. When disordered sleep and MOH coexist, both pain severity and treatment failure rates increase, and even after successful detoxification, one-year relapse rates run between 20 and 40 percent. Understanding why requires examining the direction of the relationship, and that is where the review turns to genetics. Using Mendelian randomization, a technique that employs germline genetic variants as instruments to probe causality, a bidirectional two-sample analysis found that genetic liability to insomnia was significantly associated with migraine risk in both a discovery dataset and an independent validation dataset. The reverse pathway, migraine causing insomnia, showed only a nominal effect that did not replicate, with a confidence interval spanning the null.

The authors are careful about what this genetic evidence can and cannot support. The insomnia instruments were derived from UK Biobank’s single self-reported question about trouble falling or staying asleep, capturing broad insomnia liability rather than formally diagnosed chronic insomnia disorder. More importantly, the migraine instruments were built for migraine broadly defined, not for the MOH transition specifically, which involves analgesic overuse behavior, opioid neuroadaptation and pharmacologically driven sleep disruption that genome-wide association data cannot model. Significant pleiotropy was detected in one validation dataset, and sample overlap between the insomnia and migraine genetic datasets was not corrected for. All causal inferences in the review therefore apply to migraine risk as a proxy, not to the MOH phenotype directly, and the authors call for future genetic studies using cohorts phenotyped strictly by ICHD-3 criteria.

In the opposite direction, the pharmacological evidence is more concrete. Each drug class overused in MOH disrupts sleep through mechanisms intrinsic to its own molecular pharmacology. Opioids suppress orexinergic neuronal firing and truncate slow-wave sleep. Barbiturates and benzodiazepines fragment sleep continuity and suppress REM architecture. Triptans may perturb sleep-related serotonergic pathways, though the clinical significance of chronic effects remains poorly characterized. These are not side effects in any conventional sense; they are direct consequences of engaging the same molecular targets that regulate restorative sleep. Withdrawal studies reinforce this direction of causation: in randomized comparisons and prospective cohorts, patients who achieved medication cessation reported improvements in headache frequency, with parallel gains in self-reported sleep quality described after withdrawal, though sleep was not a pre-specified outcome in the controlled trials.

The mechanistic heart of the review lies in three overlapping neurobiological substrates. The first is the orexin system, a cluster of hypothalamic neurons that project to the periaqueductal gray, the trigeminocervical complex, the rostral ventromedial medulla, the locus coeruleus and the dorsal raphe, structures that each play dual roles in wakefulness maintenance and descending pain inhibition. Animal work shows that selective activation of the orexin 1 receptor attenuates trigeminovascular nociceptive signaling, while blockade amplifies it. The only human biomarker data specific to MOH, however, point in an unexpected direction: in a cerebrospinal fluid study of 30 MOH patients, 27 with chronic migraine and 20 controls, orexin-A was significantly elevated in MOH and correlated positively with both monthly drug intake and substance-dependence scores. Whether this elevation reflects a compensatory antinociceptive response, a stress-induced hypothalamic reaction, or a mechanism tied to drug-seeking behavior remains unresolved, and the authors flag this orexinergic paradox as a key translational question.

The second substrate is melatonin and the circadian system. Melatonin’s nocturnal secretion by the pineal gland serves as the primary timing signal for the circadian clock, and it also carries documented analgesic and anti-inflammatory activity independent of its sleep-promoting effects. Altered circadian signaling has been proposed as a contributor to headache chronification, and genetic variants in CK1δ, a regulator of clock timing, associate independently with both sleep disorders and migraine susceptibility, raising the possibility that some patients carry a constitutive circadian vulnerability predisposing them to both conditions. A single randomized trial of nightly melatonin 3 milligrams showed significant reduction in migraine frequency versus placebo, though whether the mechanism is circadian stabilization, direct analgesia, or both is not established. The third substrate is neuroinflammation: even brief sleep restriction upregulates interleukin-1 beta, tumor necrosis factor alpha and interleukin-6, activates microglia and astrocytes, and impairs the glymphatic clearance of neuroactive metabolites, while chronic analgesic overuse adds a second inflammatory wave through toll-like receptor 4 signaling on glial cells. Together these loops may lower the pain threshold, drive further medication use and fragment sleep in a self-reinforcing cycle.

Sleep architecture itself tells part of the story. During slow-wave sleep, the thalamocortical system dampens sensory relay and raises the pain threshold, while during REM sleep monoaminergic descending inhibition drops to near zero, leaving the nervous system exposed to incoming nociceptive signals. Polysomnographic studies in this population document shortened total sleep time, increased nocturnal arousals, reduced slow-wave sleep duration and diminished slow-wave amplitude, a profile that offers a mechanistically coherent explanation for the morning headaches that characterize the condition. Clinically, the picture is recognizable once one knows to look for it: nearly constant dull pressure that periodically escalates, morning headache on waking, and a non-restorative quality of sleep in which patients wake exhausted regardless of hours in bed. Notably, the insomnia often persists even in patients without overt mood disturbance, suggesting that in at least a subset of cases it reflects primary neurobiological dysregulation rather than simple pain-induced wakefulness.

Two comorbidities compound the problem. Obstructive sleep apnea is substantially more prevalent among chronic migraine patients than in headache-free controls, and when apnea and insomnia coincide, the so-called COMISA phenotype, the resulting subgroup is distinctly harder to treat, with recurrent nocturnal hypoxia providing a trigeminovascular stimulus that medication withdrawal cannot eliminate. Untreated anxiety or depression at baseline similarly predicts poorer detoxification response and higher relapse. Against this backdrop, the authors argue that sequential management, detoxify first, treat sleep later, leaves the insomnia-driven component of central sensitization intact during the most fragile phase of recovery, while behavioral sleep treatment attempted during ongoing analgesic overuse is neutralized by the drugs’ pharmacological disruption of sleep. They propose, explicitly as a hypothesis, that concurrent medication withdrawal, cognitive behavioral therapy for insomnia, preventive pharmacotherapy including anti-CGRP monoclonal antibodies, and CPAP where indicated may outperform sequential care, though no randomized trial has ever tested this.

The review is candid about the gaps that temper its claims. Virtually every withdrawal study measured sleep by questionnaire; no polysomnographic evidence exists that sleep architecture objectively recovers after detoxification, and how recovery might differ across drug classes is unknown. Anti-CGRP antibodies have shown benefit in post-hoc analyses of chronic migraine trials with medication overuse, but none pre-specified sleep endpoints, and dual orexin receptor antagonists, which preserve slow-wave and REM sleep unlike benzodiazepines, carry a directionally uncertain rationale given the paradoxically elevated orexin-A in MOH cerebrospinal fluid. The authors’ prescription is a defined research agenda: a randomized trial of concurrent withdrawal, CBT-I and preventive pharmacotherapy versus detoxification alone, with polysomnographic sleep architecture and one-year relapse as co-primary endpoints. Insomnia in MOH, they conclude, is not a symptom waiting passively for the headache to resolve, but a sustaining mechanism in its own right, and treating it from the outset may prove to be what separates durable remission from repeated cycles of detoxification and relapse.

Subject of Research: The reciprocal neurobiological relationship between insomnia and medication overuse headache

Article Title: Insomnia and medication overuse headache: neurobiological links, reciprocal interactions, and integrated therapeutic strategies

Article References: Cotrik, E., Krymchantowski, A. V., Jevoux, C., Caldas Ferreira, I., Monteiro Auler, L., Ferreira Fontoura Sousa, M. C., & Marcussi, A. P. (2026). Insomnia and medication overuse headache: neurobiological links, reciprocal interactions, and integrated therapeutic strategies. Frontiers in Pain Research, 7, Article 1911261. https://doi.org/10.3389/fpain.2026.1911261

Image Credits: AI Generated

DOI: 10.3389/fpain.2026.1911261

Keywords: medication overuse headache, insomnia, migraine, orexin, melatonin, neuroinflammation, CBT-I, CGRP, sleep apnea, detoxification, Mendelian randomization, central sensitization

The core insight is that three large bodies of research have grown up largely in isolation. One line of work shows that people with chronic low back pain often perceive their back differently, reporting a diminished sense of connection to it or uncertainty about its size and position. A second documents changes in the motor cortex’s control of trunk muscles, including shifted and enlarged cortical maps of the deep abdominal muscle transversus abdominis in people with recurrent pain. A third reveals altered pain processing, from heightened sensitivity to pressure at sites far from the back to less efficient endogenous pain modulation. What has never been done, the author notes, is measuring all three domains concurrently in the same well-characterized cohort, leaving open whether they covary, which comes first, and whether any of them explains the others.

To organize these threads, the framework borrows from predictive coding, a computational theory of the brain formalized by Karl Friston. Under this view, the brain constantly predicts incoming sensory signals and updates its internal models when prediction errors accumulate. Movement, in the related active-inference account, is not commanded top-down but emerges as the body fulfills proprioceptive predictions. Applied to back pain, the hypothesis is that persistent nociceptive input or altered sensorimotor processing could disrupt the updating of predictions about trunk state, allowing mismatches between predicted and actual bodily signals to persist. That persistent mismatch could then couple distorted trunk-state estimation to changes in motor regulation, bodily perception, and pain processing in a mutually reinforcing loop.

The focal candidate mechanism is the body schema, the action-oriented, largely unconscious representation that supports movement planning and online control. Crucially, the author is careful about measurement. No existing instrument directly measures the body schema; researchers rely on proxies such as the left/right judgment task, which is interpreted as indexing implicit motor imagery; the lumbar two-point discrimination threshold, a behavioral index of tactile-spatial acuity; and the Fremantle Back Awareness Questionnaire, a self-report measure of conscious back-perception disturbance. Each captures a different phenomenon, and their reliability, measurement error, and construct structure in low back pain remain incompletely established.

The empirical evidence is suggestive but uneven. Studies have found higher lumbar two-point discrimination thresholds in people with chronic low back pain, sometimes linked to greater gray-matter volume in the back region of primary somatosensory cortex and altered S1-thalamic connectivity. Elevated thresholds appear most clearly in subgroups with predominant central-sensitization features, hinting that these disturbances may characterize only part of the population. Laterality-judgment findings are heterogeneous, with some studies showing slower or less accurate trunk judgments and others finding preserved performance with altered brain responses. Self-reported back-perception disturbance, meanwhile, is consistently higher in patients and correlates with pain, disability, catastrophizing, and psychological distress.

On the motor side, transcranial magnetic stimulation studies reveal a complex picture. Some abnormalities appear in remote muscles such as the hand, suggesting a generalized change in motor-system state rather than a trunk-specific one. Trunk-muscle mapping studies have shown shifted cortical representations of transversus abdominis associated with delayed anticipatory muscle activation, and reduced map volume with loss of spatial separation between deep back muscles. A recent systematic review and meta-analysis of thirty-three studies found low to moderate certainty evidence for lower paraspinal corticospinal excitability, but concluded that findings must be interpreted separately by target muscle and outcome rather than collapsed into a single corticomotor abnormality.

Pain processing forms the third domain, operationalized through pressure pain thresholds, temporal summation of pain, and conditioned pain modulation. Meta-analytic evidence indicates less efficient conditioned pain modulation in chronic low back pain, while facilitated temporal summation appears in both acute and chronic presentations. The framework insists these psychophysical measures be kept distinct from related but non-interchangeable concepts such as nociplastic pain criteria, central sensitization, and Central Sensitization Inventory symptom burden. Notably, a recent multivariate imaging study found preserved mechanoreceptive somatotopy in the somatosensory and motor cortices of patients despite their greater self-reported back-perception disturbance, arguing against simple cortical map degradation as a necessary explanation and sharpening the question of what, exactly, is altered.

Because the directional architecture remains untested, the framework lays out four competing models: a body-representation-led account in which miscalibrated trunk-state estimation organizes the other domains; a pain-processing-led account in which altered pain sensitivity drives perceptual and motor changes; a motor-system-led account in which altered movement changes the sensory evidence available for updating body models; and a shared-upstream account in which threat learning, attention, affective state, or systemic influences generate parallel variation without direct causation among the domains. Fear and avoidance could occupy different positions in each, acting as upstream drivers, mediators, or consequences. Once reciprocal feedback develops, different initiating architectures may produce increasingly similar cross-sectional patterns, which is why the author treats mutual reinforcement as a maintenance process rather than a fifth initiating model.

To make the framework falsifiable, the paper specifies a construct-validity prerequisite and four predictions. First, body-representation measures should add reproducible explanatory information about corticomotor and pain-processing outcomes beyond pain intensity, disability, psychological variables, and nociplastic features. Second, those cross-domain associations should be stronger when independently assessed nociplastic features converge. Third, interventions designed to recalibrate trunk-state estimation should produce change in a valid target indicator that then predicts or mediates change in motor regulation and pain processing, beyond expectancy and general treatment effects. Fourth, longitudinal cohorts should test whether early change in body-representation measures predicts later motor or pain outcomes, comparing all four architectures in formal model comparison.

The clinical stakes are considerable. If a valid indicator of trunk-state estimation could be selectively changed and that change shown to precede improvements in motor control and pain, it would offer a precisely specified sensorimotor entry point for rehabilitation, distinguishable from placebo, belief change, or task practice. Existing evidence offers only partial precedent: a mediation analysis of education and graded sensorimotor retraining found the largest indirect effects through back beliefs, catastrophizing, and self-efficacy, with a smaller effect through back self-perception and no support for tactile acuity as a mediator. The author is candid that the incremental value of the broader body-representation domain and the mechanistic independence of the narrower body-schema component remain open empirical questions. What the framework delivers is a rigorous roadmap, converting a diffuse family of observations into specific, disconfirmable predictions that could reshape how chronic back pain is understood and treated.

Subject of Research: Altered body representation, corticomotor function, and pain processing in chronic non-specific low back pain

Article Title: Altered body representation in chronic non-specific low back pain: a testable framework linking body-schema-related disturbance, corticomotor alterations, and altered pain processing

Article References: Xie, Z. (2026). Altered body representation in chronic non-specific low back pain: a testable framework linking body-schema-related disturbance, corticomotor alterations, and altered pain processing. Frontiers in Pain Research, 7, Article 1899538. https://doi.org/10.3389/fpain.2026.1899538

Image Credits: AI Generated

DOI: 10.3389/fpain.2026.1899538

Keywords: chronic low back pain, body schema, body representation, predictive coding, corticomotor control, pain processing, somatosensory cortex, nociplastic pain, central sensitization, transcranial magnetic stimulation, motor imagery, sensorimotor integration

The article, authored by Denise Franco de Almeida Duarte, Jader Vinicius da Silva Rocha, and colleagues from the Federal University of Espírito Santo, Santa Catarina State University, and the Baylor Scott & White Research Institute, advances a deliberately cautious hypothesis. The researchers propose that when a headache persists months after a traumatic brain injury, its persistence may serve as a clinical signal warranting investigation of ongoing functional or biological abnormalities that are not fully characterized by structural imaging. Crucially, the authors are explicit about what they are not claiming: persistent post-traumatic headache is not proposed as a validated biomarker, a prognostic indicator, or a surrogate measure of any specific underlying mechanism. Instead, they frame it as an observable clinical feature whose persistence should prompt scientists and clinicians to look deeper.

The motivation for this framework comes from a well-recognized gap in traumatic brain injury care. Acute severity measures such as the Glasgow Coma Scale, pupillary reactivity, and structural imaging remain essential for early clinical decisions and are strongly associated with mortality and short-term disability. However, these tools were designed to characterize the initial injury and estimate acute outcomes, and their ability to account for persistent symptoms is limited. Patients with apparently similar initial injury profiles can follow markedly different long-term trajectories, with some experiencing persistent headache, fatigue, cognitive impairment, sleep disturbances, emotional symptoms, and reduced quality of life while others recover more fully. This variability suggests that the extent of the initial injury alone does not capture the biological processes that shape long-term recovery.

One candidate process is neuroinflammation. Traumatic brain injury initiates a cascade of biological events that can extend well beyond the acute phase. Acute activation of microglia and astrocytes, the brain’s resident immune cells, contributes to tissue responses following injury, but experimental studies suggest that sustained or dysregulated inflammatory activity may persist, potentially altering the blood-brain barrier and disrupting neuronal function. Animal work has shown that chronic cortical inflammation mediated by microglia can drive neuronal dysfunction long after the initial trauma, and microglial depletion during the chronic phase of experimental injury has been reported to reduce neurodegeneration and neurological deficits. The authors, however, are careful to note that evidence for persistent neuroinflammation derives predominantly from experimental studies and broader traumatic brain injury populations, and should not be interpreted as proof that neuroinflammation directly causes persistent post-traumatic headache. It provides a biologically plausible framework that requires specific validation in patients with the condition.

Altered pain processing offers a second, and in some respects better-supported, line of evidence. Studies conducted specifically in patients with persistent post-traumatic headache have identified sensory abnormalities, including cephalic allodynia, hyperalgesia, and altered pain modulatory responses, supporting abnormal nociceptive processing in at least a subset of patients. The authors emphasize that central sensitization should be distinguished from nociplastic pain and other forms of altered nociceptive signaling, because these related concepts are not interchangeable. Adding to this picture, experimental work has demonstrated hypersensitivity to calcitonin gene-related peptide, or CGRP, a key molecule in headache biology, in people with post-traumatic headache, lending support to the involvement of CGRP-related nociceptive pathways. Even so, these findings do not establish central sensitization as a universal mechanism or demonstrate a single pathophysiological pathway underlying the condition.

A complementary perspective comes from network neuroscience, which conceptualizes neurological dysfunction as arising from disturbances in interactions among distributed brain networks rather than exclusively from focal structural damage. Traumatic brain injury studies have demonstrated persistent structural network abnormalities during recovery, and neuroimaging studies focused on post-traumatic headache have identified alterations in resting-state functional connectivity involving pain-processing, pain-modulatory, and affective networks. One particularly striking finding involved disruption of functional connectivity between the periaqueductal gray, a brainstem region central to pain modulation, and the default mode network, which predicted the development of persistent post-traumatic headache in patients with mild traumatic brain injury. These findings provide more direct, though still limited, evidence that persistent headache may be associated with measurable alterations in brain network function.

The authors also confront an important alternative explanation: persistent post-traumatic headache may simply reflect a greater overall symptom burden rather than a distinct biological state. Headache commonly co-occurs with sleep disturbance, fatigue, cognitive complaints, anxiety, and depression, and these factors may independently influence both headache persistence and measures of brain function. Pre-existing headache disorders, injury severity, medication use, cervical or extracranial pain generators, and psychological and behavioral factors may further contribute to clinical heterogeneity. Consequently, the presence or severity of persistent headache cannot currently be assumed to indicate the presence, type, or magnitude of persistent brain dysfunction. The co-occurrence of headache with other post-traumatic symptoms may reflect partially overlapping, independent, or mutually reinforcing mechanisms rather than different expressions of a single persistent biological condition.

What distinguishes this opinion article is that it generates testable predictions rather than resting on plausibility alone. If persistent post-traumatic headache is genuinely associated with ongoing post-traumatic dysfunction beyond overall symptom burden, then individuals with the condition should demonstrate reproducible functional or biological abnormalities when compared with appropriately matched traumatic brain injury survivors who do not have persistent headache. These associations should remain detectable after accounting for injury severity, pre-existing headache, headache phenotype, psychological symptoms, sleep disturbance, and medication use. Longitudinal studies should further determine whether changes in headache frequency, intensity, or disability are accompanied by changes in candidate neurophysiological, neuroimaging, or molecular measures. Conversely, the authors note, failure to identify reproducible associations after controlling for confounders would argue against the hypothesis or restrict its applicability to specific patient subgroups.

Testing the hypothesis will require prospective studies that combine detailed headache phenotyping with objective measures of brain function and biology. Quantitative electroencephalography, neuroimaging-derived connectivity measures, and molecular or inflammatory markers are candidate approaches, and artificial intelligence and machine-learning methods may help identify multidimensional patterns or patient phenotypes within these datasets. The authors stress, however, that machine learning is an analytical tool rather than a biological measure, and that no candidate approach can currently be considered a validated biomarker of persistent post-traumatic headache. Their value lies in testing whether persistent headache is systematically associated with measurable patterns of post-traumatic dysfunction beyond headache severity and overall symptom burden. Candidate measures should not be treated as biomarkers until their reproducibility, specificity, longitudinal behavior, and clinical relevance have been established in affected populations.

The practical implications could be significant if the framework survives prospective validation. Traumatic brain injury remains a major cause of death and disability worldwide, particularly among young adults and people of working age, and advances in prehospital care, neurosurgery, and intensive care have improved survival while increasing attention to long-term quality of life. A clinically accessible signal, such as a headache that refuses to resolve, could eventually help identify survivors who might benefit from additional biological assessment, prognostic stratification, or mechanism-based interventions. The authors recommend that future research compare traumatic brain injury survivors with persistent headache, survivors without persistent headache, and, where appropriate, individuals with primary headache disorders, to determine which findings are specific to the post-traumatic condition, to traumatic brain injury more broadly, or to chronic headache irrespective of trauma. Stratification by injury severity will also be necessary, because mechanisms and recovery trajectories may differ between mild and moderate-to-severe injury. For now, the message is one of disciplined optimism: persistent post-traumatic headache may offer a window into the injured brain, but the view through it must still be verified.

Subject of Research: Post-traumatic headache as a clinical indicator of persistent brain dysfunction after traumatic brain injury

Article Title: Post-traumatic headache as a window into persistent brain dysfunction after traumatic brain injury: an opinion article

Article References: Duarte, D. F. D. A., Rocha, J. V. D. S., Dias, F. M. V., Koerich, M. H. A. D. L., Almeida, V. C. R. D., Almeida, R. F. D., Silva Filho, W. G. D., & Arêas, F. Z. D. S. (2026). Post-traumatic headache as a window into persistent brain dysfunction after traumatic brain injury: an opinion article. Frontiers in Human Neuroscience, 20, Article 1946999. https://doi.org/10.3389/fnhum.2026.1946999

Image Credits: AI Generated

DOI: 10.3389/fnhum.2026.1946999

Keywords: post-traumatic headache, traumatic brain injury, neuroinflammation, central sensitization, brain connectivity, CGRP, Glasgow Coma Scale, functional connectivity, biomarkers, network neuroscience, neurorehabilitation, mild TBI

The study, led by Jun Liu, Wenheng Chen and Shan Gao of Zhumadian Central Hospital in China, followed 624 patients who underwent primary unilateral total knee arthroplasty, the technical term for a complete artificial knee replacement. Instead of relying only on pain intensity scores, the researchers asked patients to complete whole-body pain drawings at two weeks, six weeks, and three months after their operation. On these standardized body silhouettes, patients shaded every region where they had felt pain during the previous week. A semiautomated image-processing pipeline built on Python, OpenCV, SimpleITK and scikit-image then scanned, aligned and quantified these drawings, converting the shaded areas into a single number called the Pain Extent Index, or PEI: the percentage of body surface area marked as painful.

The technical machinery behind this measurement was rigorous. Paper drawings were scanned at high resolution and electronic drawings were exported as lossless image files, then corrected for orientation, stripped of stray annotations, and registered to a standardized anatomical template using affine and nonrigid registration. Every processed map passed through structured quality control, with flagged images independently reviewed and resolved by consensus. Reproducibility testing on a 20 percent sample of patients produced strikingly high agreement: the inter-rater intraclass correlation coefficient for the PEI was 0.987, and the median Dice coefficient, a measure of overlap between independently processed pain masks, was 0.949. In other words, two different analysts processing the same drawing arrived at nearly identical maps of where the patient hurt.

With the PEI quantified at each visit, the team calculated a patient-specific contraction velocity, essentially the rate at which the spatial footprint of pain shrank between two weeks and three months. This was done with linear mixed-effects modeling, a statistical technique that estimates both a population-average trajectory and an individual slope for each patient. Across the whole cohort, the median contraction rate was about 0.065 log units per week, meaning most patients’ pain maps contracted substantially during the subacute phase. But the spread was wide, and that spread turned out to matter enormously. Patients who went on to report moderate-to-severe knee pain at twelve months contracted at only about half the rate of those who recovered well, and roughly one in five of them actually showed spatial pain expansion rather than contraction.

The headline result is statistically robust. At twelve months, 92 patients, or 14.7 percent of the cohort, met the strict definition of persistent moderate-to-severe operated-knee pain, which required a pain score of at least four out of ten, pain on at least four days per week, and continuous or recurrent pain lasting at least three months. Each standard deviation of slower spatial contraction was associated with 42 percent higher odds of falling into this group, even after the researchers adjusted for age, sex, body mass index, comorbidities, preoperative pain intensity, preoperative pain extent, psychological factors such as catastrophizing and anxiety, neuropathic pain features, and crucially, the static pain measurements taken at both ends of the recovery window. That final adjustment is the study’s key innovation: knowing where a patient’s pain stood at two weeks and at three months still did not explain away the signal carried by the rate of change itself.

The pattern held up under an unusually thorough battery of sensitivity analyses. The association persisted when the exposure was redefined as absolute PEI change, relative contraction rate, time-weighted pain-area burden, or slopes restricted to the operated limb or the knee alone. A Bayesian joint model that explicitly accounted for uncertainty in the estimated slopes yielded a similar result, with a posterior odds ratio of 2.05. When the researchers excluded the twelve patients whose twelve-month pain had an adjudicated alternative explanation, such as infection or a mechanical prosthesis problem, the association actually strengthened. Inverse-probability weighting to address missing data, and separate analyses of paper versus electronic drawings, all produced consistent estimates, suggesting the finding is not an artifact of one analytical choice.

Just as striking were the secondary outcomes. Slower spatial contraction predicted higher knee pain scores at both six and twelve months, lower scores on the KOOS-JR joint-replacement quality-of-life questionnaire, and lower Forgotten Joint Scores, which measure how completely patients stop noticing their artificial joint in daily life. Each standard deviation of slower contraction was associated with a 4.6-point drop in KOOS-JR and a 6.3-point drop in the Forgotten Joint Score, and it raised the odds of failing to achieve a clinically meaningful improvement in joint function by 46 percent. The population-level heat maps tell the story visually: in patients who recovered well, pain density around the knee swelled briefly after surgery and then collapsed toward a low plateau, while in those with persistent pain the map remained stubbornly wide from three months onward.

Why should the spatial spread of pain carry prognostic power that intensity scores lack? The authors are careful not to overclaim a mechanism, but they outline several plausible biological pathways. A pain map that refuses to shrink could reflect persistent peripheral input from the healing joint, such as ongoing inflammation or synovitis. It could indicate guarding and altered movement patterns that spread mechanical load to the thigh, lower leg and contralateral side. It could also signal central sensitization, a state in which the nervous system itself amplifies and generalizes pain signals, a phenomenon long implicated in poor arthroplasty outcomes and connected to psychological distress. A whole-body slope cannot distinguish these mechanisms, but it may integrate them into a single, clinically readable signal of whether recovery is genuinely progressing.

The clinical implications are tantalizing but deliberately cautious. Serial pain drawings are cheap, quick and, as this study demonstrates, remarkably reproducible whether collected on paper or digitally, making them a plausible addition to routine follow-up visits or even remote monitoring programs. A patient whose pain map is contracting slowly at the six-week check could prompt clinicians to look harder for wound complications, prosthesis problems, stiffness, neuropathic features, sleep disturbance or rehabilitation barriers, rather than simply waiting for the twelve-month appointment to reveal a bad outcome. The authors stress that a slow contraction rate is a signal to investigate, not a diagnosis, and certainly not an indication for automatic imaging or revision surgery, since revision outcomes vary widely depending on the underlying cause of pain.

Important limitations temper the excitement. This was a single-center retrospective analysis of prospectively collected data, so residual confounding cannot be excluded, and the cohort may not generalize to other populations or healthcare systems. Summarizing recovery with a linear slope from three time points inevitably smooths over nonlinear dynamics, and pain drawings ultimately depend on patient comprehension and recall. The study also cannot establish causality: slow contraction may be a cause of chronic pain, a consequence of an underlying pathological process, or simply another face of the same phenomenon. What it does establish is that the direction and speed of spatial pain recovery carry real prognostic information beyond anything measured at a single visit. If future multicenter studies validate the approach and demonstrate that acting on an early contraction alert improves outcomes, the humble body diagram, a tool as old as clinical medicine itself, could become a powerful digital window into how recovery is truly unfolding.

Subject of Research: Association between early postoperative contraction of spatial pain extent and persistent moderate-to-severe knee pain 12 months after total knee arthroplasty

Article Title: Early spatial pain contraction and moderate-to-severe knee pain 12 months after total knee arthroplasty: a retrospective cohort study

Article References: Liu, J., Chen, W., & Gao, S. (2026). Early spatial pain contraction and moderate-to-severe knee pain 12 months after total knee arthroplasty: a retrospective cohort study. Frontiers in Pain Research, 7, Article 1948322. https://doi.org/10.3389/fpain.2026.1948322

Image Credits: AI Generated

DOI: 10.3389/fpain.2026.1948322

Keywords: total knee arthroplasty, chronic postsurgical pain, pain extent index, pain drawings, spatial pain contraction, subacute recovery, central sensitization, KOOS-JR, prognostic markers, knee osteoarthritis, pain trajectories, mixed-effects modeling

The researchers focused on functional abdominal pain disorders, or FAPDs, a group of conditions defined by recurrent or persistent abdominal pain that cannot be explained by an organic disease. What they found was striking in its consistency. Among adolescents with FAPDs, 80.6 percent experienced multisite pain, meaning pain at two or more body sites, while 54.8 percent reported that their primary pain was actually located outside the abdomen. Headache was the most frequent accompanying complaint, with joint pain and back pain also commonly reported. In more than half of those affected, the symptoms had already persisted for at least a year, a duration that the researchers flag as a critical warning sign for clinicians and families alike.

The mechanism the researchers propose is a well-recognized concept in pain science: central sensitization. The process may begin innocently enough, for example with an infection or inflammation that triggers pain in the gut. But if the pain persists while the child is simultaneously coping with stress, anxiety, or other psychological strain, the pain-processing system may gradually become hypersensitive and remain locked in that state even after the original trigger has resolved. At that point, even relatively mild stimuli can be sufficient to generate pain, and over time entirely normal bodily processes, such as the digestion that begins after a meal, may become painful despite normally causing no discomfort at all. This offers a coherent physiological explanation for why the pain can both persist and spread to multiple parts of the body.

Dr. János Major, first author of the study, assistant professor at the Institute of Behavioural Sciences at Semmelweis University and head of the Paediatric Pain Centre at Bethesda Children’s Hospital, argues that this pattern should change how doctors approach the symptom. If a school-age child has abdominal pain, he says, it can be worth looking a little deeper and asking whether they also experience pain elsewhere. If they do, this may suggest that the pain is not simply a symptom of an organic condition, but part of a more complex pain disorder. Importantly, he notes, this can hold true even when a child carries an earlier organic diagnosis such as celiac disease or Crohn’s disease, because that diagnosed condition may no longer be what is actually causing the current symptoms.

The psychosocial dimensions of the study are equally significant. Adolescents with FAPDs were more likely than their peers to report that they faced too many assessments at school, that there was not enough peace and quiet in the classroom, or that teachers treated them unfairly. Peer exclusion and other forms of harassment were also more common in this group. The findings position the classroom and the peer group not as incidental backdrops to the illness but as active contributors to its onset and persistence, aligning functional pain disorders with the broader literature on how chronic stress shapes pain perception in young people.

To quantify the broader toll, the researchers examined health-related quality of life, commonly abbreviated HRQOL, across four domains. Physical functioning was assessed alongside emotional functioning, social functioning, and everyday school functioning. The emotional questions covered issues including fear, sadness, anger, sleep problems, and worries. Social functioning looked at how children got along with their peers, including whether they were excluded or teased and how well they managed to fit in. School functioning captured factors such as the ability to concentrate and keep up with schoolwork, as well as how many school days were missed because of feeling unwell or attending medical appointments.

The results on quality of life were sobering. Adolescents with FAPDs scored significantly worse across every area assessed, and 14.5 percent had overall HRQOL scores falling in the extremely low range. Verbal harassment, including teasing, mocking, and name-calling, was itself associated with extremely low HRQOL scores, underlining how damaging persistent social victimization can be when combined with chronic pain. Those affected also missed more days of school than their peers, and regular analgesic use was more common among them, a pattern that raises additional concerns about medication reliance at a young age.

The research team is emphatic that these symptoms deserve to be taken seriously rather than dismissed. Without treatment, the underlying factors do not necessarily resolve on their own, and the pain may persist into adulthood, significantly affecting quality of life and everyday functioning. Over the longer term, persistent severe pain can place a substantial burden on health care systems, lead to difficulties maintaining employment, and, in severe cases, even result in early disability. The trajectory from a childhood complaint that adults may be tempted to minimize to a lifelong, costly condition is precisely what early recognition is meant to interrupt.

Dr. Szilvia Ádám, last author of the study and associate professor at the Health Services Management Training Center at Semmelweis University, points to a common parental reflex that can delay that intervention. Parents often tend to play the problem down, she observes, saying that it will pass or that the child will grow out of it. The difficulty, she explains, is that the factors triggering or maintaining the pain do not necessarily disappear on their own. A symptom landscape shaped by sensitized pain pathways, school-related stress, and peer harassment is not one that reliably fades with time; in many cases it consolidates, embedding itself in the child’s developing nervous system and social world.

There is, however, a genuinely hopeful conclusion embedded in the findings. With appropriate support, the condition can be treated successfully. In some cases, even a change of schools or a short course of psychotherapy can make a considerable difference, and pain treatment initiated in childhood may reduce the likelihood that the pain will persist or recur in adulthood. For parents, pediatricians, and teachers, the practical message is concrete: when a child presents with recurrent abdominal pain, the essential follow-up questions are whether the child hurts anywhere else, whether the pain has lasted a year or more, and what is happening in the classroom and the peer group. Asking those questions early, the study suggests, may be the single most effective step toward preventing a temporary complaint from becoming a permanent condition.

Subject of Research: Functional abdominal pain disorders in school-age children and their association with psychosocial stress and multisite pain

Article Title: Frequent abdominal pain in children may be associated with school-related stress and peer harassment

Article References: Frequent abdominal pain in children may be associated with school-related stress and peer harassment. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: functional abdominal pain disorders, Semmelweis University, children, adolescents, central sensitization, school stress, peer harassment, bullying, quality of life, pediatric pain, International Journal of Pediatrics, multisite pain

The headline finding is the sheer variability of the numbers. Among established long-term survivor cohorts, chronic pain prevalence ranged from 8.6 percent to 67.1 percent, a nearly eightfold spread that reflects differences in cancer type, treatment regimens, time since treatment, and how pain itself was measured. Head and neck cancer survivors, breast cancer survivors treated with surgery and radiotherapy, and patients who received neurotoxic chemotherapy all feature prominently in the evidence base. The authors caution that this heterogeneity is not simply statistical noise; it signals that chronic pain after cancer is not one condition but a family of conditions with different biological origins and different trajectories.

To understand why pain persists long after tumors are removed, the review turned to modern mechanistic classifications of chronic pain. Neuropathic pain, caused by direct damage or disease affecting the somatosensory nervous system, emerged as the most frequently reported mechanism across the included studies. This is biologically plausible: surgical dissection can sever peripheral nerves, radiation can injure nerve plexuses, and chemotherapeutic agents such as taxanes and platinum compounds are well known for causing peripheral neuropathy. In colorectal cancer survivors followed for up to eleven years in population-based registry studies, chemotherapy-induced neuropathy was associated with measurably worse quality of life, and in head and neck populations, radiation-induced nervous system complications were linked to persistent pain syndromes.

But the review also highlights a more controversial and scientifically intriguing category: nociplastic pain. Introduced into the International Classification of Diseases through the International Association for the Study of Pain’s ICD-11 framework, nociplastic pain arises from altered nociceptive processing despite no clear evidence of actual or threatened tissue damage or of a lesion in the somatosensory system. Some survivor populations in the review showed symptom profiles consistent with this mechanism, including patterns suggestive of central sensitization, in which the central nervous system becomes hyperexcitable and amplifies pain signals. Breast cancer survivor cohorts assessed with instruments such as the Central Sensitization Inventory showed that a subset of patients experience pain that cannot be explained by nerve damage or tissue injury alone.

Here the authors insert an important scientific caveat. Most mechanistic classifications in the reviewed studies were based on screening instruments and symptom questionnaires rather than diagnostic confirmation through quantitative sensory testing or other objective measures. Central sensitization, in particular, remains a construct that is easy to describe but difficult to verify. The certainty of evidence across the three outcome domains of prevalence, mechanism, and psychological impact was evaluated using the GRADE framework, and the authors are candid that the mechanistic evidence remains suggestive rather than definitive. This is a call to the research community: the field needs rigorous phenotyping studies that combine psychophysical testing, imaging, and longitudinal follow-up to move beyond symptom-based surrogates.

The psychological toll of persistent pain emerges as the review’s most consistent finding. Across the included studies, cancer survivors with chronic pain reported higher levels of anxiety, more severe depressive symptoms, greater emotional distress, and poorer quality of life than pain-free survivors. This comorbidity is not incidental. Decades of research on depression and pain comorbidity show that the two conditions share neurotransmitter pathways and amplify each other in a vicious cycle: pain disrupts sleep, sleep loss lowers pain thresholds and worsens mood, and depression reduces the motivation and energy needed for rehabilitation and self-management. Studies in the review found that post-traumatic stress symptoms arising from multiple cancer-related stressors predicted chronic pain, and that pain catastrophizing, the tendency to ruminate and magnify pain, was elevated in survivors with refractory postsurgical pain.

The functional consequences extend beyond mood. Research on working-age survivors has linked chronic pain to reduced health-related quality of life and to difficulties maintaining employment, a burden with obvious economic and social dimensions. For head and neck cancer survivors, pain often coexists with difficulties in swallowing, speaking, and shoulder function, compounding the impact on daily life. In breast cancer populations, persistent pain after treatment has been described as an underreported burden, with many patients never raising the issue during follow-up visits and clinicians rarely asking. The review’s implications section is direct: survivors should report ongoing pain and emotional symptoms, and survivorship care should include routine assessment of both.

Methodologically, the review is a model of transparency. The authors searched five major databases, PubMed, Scopus, Web of Science, Embase, and PsycINFO, registered their protocol prospectively in PROSPERO, appraised methodological quality with the Joanna Briggs Institute critical appraisal tools, and followed the PRISMA 2020 reporting guidelines. The included studies were predominantly cross-sectional and cohort designs covering a wide range of malignancies, from melanoma and testicular cancer to colorectal, breast, lung, and prostate cancers. No new primary data were generated; the analysis is entirely a synthesis of previously published work, with supporting data available in the article’s supplementary materials.

What should clinicians and patients take away from this body of evidence? First, chronic pain after cancer is common enough that it should be screened for systematically, not discovered only when a patient volunteers the information. The American Society of Clinical Oncology has long had a clinical practice guideline for managing chronic pain in adult cancer survivors, yet the review suggests that long-term care strategies remain lacking in practice. Second, because the mechanisms differ, treatment should differ: neuropathic pain may respond to different classes of medication than nociplastic pain, which often benefits from exercise, cognitive behavioral approaches, and centrally acting strategies. Multidimensional pain assessment, covering sensory qualities, psychological state, sleep, and function, is the practical corollary of the review’s mechanistic message.

Finally, the review identifies where science must go next. Stronger mechanistic research is needed to distinguish reliably between neuropathic, nociceptive, and nociplastic contributions in individual patients, and longitudinal studies should track how pain phenotypes evolve from the end of treatment into long-term survivorship. Emerging tools, including wearable devices capable of continuously monitoring pain-related parameters, may eventually help predict which patients are at highest risk before pain becomes entrenched. For now, the message for the growing global population of cancer survivors is clear: pain that persists after treatment is a medical condition in its own right, it is strongly linked to mental health, and it deserves the same systematic attention that surveillance for cancer recurrence already receives.

Subject of Research: Prevalence, mechanisms, and psychological outcomes of chronic pain in cancer survivors

Article Title: Prevalence, mechanisms, and psychological outcomes of chronic pain in cancer survivors: a systematic review with narrative synthesis

Article References: Myrzabay, Z., & Viderman, D. (2026). Prevalence, mechanisms, and psychological outcomes of chronic pain in cancer survivors: a systematic review with narrative synthesis. Journal of Cancer Survivorship. https://doi.org/10.1007/s11764-026-02138-7

Image Credits: AI Generated

DOI: 10.1007/s11764-026-02138-7

Keywords: cancer survivors, chronic pain, neuropathic pain, nociplastic pain, central sensitization, psychological outcomes, quality of life, systematic review, chemotherapy-induced neuropathy, survivorship care, depression, anxiety

The research, led by Laura E. Laumann of Brown University and Dean G. Cruess of the University of Connecticut, set out to answer two questions that have largely been ignored in the existing literature. First, do young adults with chronic pain that spans multiple body regions actually feel worse than those whose pain is more localized? Second, are specific clusters of PTSD symptoms, rather than posttraumatic stress as an undifferentiated whole, associated with the odds of having multi-region pain? The distinction matters clinically, because PTSD is not a monolith. Under the DSM-5 framework, its symptoms organize into four clusters: intrusion, avoidance, negative alterations in cognition and mood, and alterations in arousal and reactivity, the last of which encompasses hyperarousal symptoms such as exaggerated startle, hypervigilance, sleep disturbance, and irritability.

The study enrolled 123 young adults with chronic pain, with an average age of 19 years, roughly 71 percent of whom identified as White and about 71 percent of whom were female. Participants completed baseline measures as part of a larger study, and the researchers used the Michigan Body Map to chart where on the body each person experienced pain. The map, initially validated by a team at the University of Michigan, divides the body into distinct regions and allows clinicians and researchers to quantify pain distribution with a simple self-report instrument. The team defined multi-region pain as pain present in five or more regions, a threshold that captures the kind of widespread, dispersed pain burden long associated with conditions such as fibromyalgia and with substantially worse health outcomes.

The first answer was unambiguous. Young adults whose pain reached five or more body regions reported significantly greater pain severity than those with more localized pain, scoring 5.6 on average compared with 4.8. The gap in daily functioning was even more striking. Pain interference, a measure of how much pain disrupts activities such as work, sleep, and social life, showed a median of 57 in the multi-region group versus 32.5 in the localized group. Because the interference data were skewed, the researchers used the nonparametric Mann-Whitney U test to confirm that the difference in mean ranks was statistically significant, reporting medians simply for ease of interpretation. In practical terms, widespread pain in this age group was not merely a matter of more sore spots; it translated into measurably heavier disruption of everyday life.

The second answer was more nuanced and, ultimately, more consequential. When the researchers ran separate logistic regression models, adjusting for gender, they found that total PTSD symptoms and each of the four symptom clusters individually were significantly and positively associated with the odds of having multi-region pain. In other words, intrusion symptoms, avoidance symptoms, mood and cognition symptoms, and hyperarousal symptoms each predicted widespread pain on their own. That pattern is consistent with a growing body of work linking trauma-related distress to pain that refuses to stay confined to a single anatomical site.

But the picture changed when all four clusters were entered into the model simultaneously. In that head-to-head comparison, only one cluster retained a significant independent association with multi-region pain: hyperarousal. Each unit increase in hyperarousal symptoms raised the odds of multi-region pain by 13 percent, an odds ratio of 1.13 with a 95 percent confidence interval of 1.01 to 1.27. The confidence interval is narrow enough to signal a reliable effect, though its lower bound hovers close to the threshold of significance, a reminder that the estimate carries some uncertainty in a sample of this size. Still, the pattern is telling. When clusters are modeled separately, they overlap heavily, sharing variance with one another and with total symptom burden. Only when that shared variance is partitioned does the unique contribution of each cluster emerge, and in this sample it was hyperarousal that stood alone.

Why would a state of heightened physiological arousal be linked to pain that spreads across the body? The most compelling mechanistic account involves central sensitization, a process in which the central nervous system itself becomes amplified in its response to stimuli. In sensitized states, neurons in the spinal cord and brain become hyperexcitable, so that signals that would ordinarily register as mild pressure or ordinary movement are interpreted as pain. Researchers such as Clifford Woolf have described central sensitization as a key to understanding chronic pain that cannot be explained by tissue damage alone, and neuroimaging and psychophysical studies from networks such as the MAPP Research Network have linked sensory amplification to broader symptom spread and severity. Hyperarousal, with its sustained activation of the sympathetic nervous system and dysregulation of the hypothalamic-pituitary-adrenal axis, is precisely the kind of chronic physiological state that could promote and maintain such amplification.

Sleep provides another plausible bridge. Hyperarousal symptoms include sleep disturbance, and the relationship between disrupted sleep and pain is well documented in both directions. Polysomnography studies in people with PTSD have documented altered sympathetic activity and abnormal hypothalamic-pituitary-adrenal dynamics during sleep, and sleep loss is known to lower pain thresholds and intensify pain perception. A young adult caught in a loop of hypervigilant nights and painful days may find that each factor feeds the other, with poor sleep amplifying next-day pain, and pain further fragmenting sleep. The authors of the new study are careful to note that their cross-sectional design cannot establish which comes first, and they explicitly call for longitudinal research to identify mechanisms and clarify the directionality of the relationships they observed.

The clinical implications, however, are already taking shape. If hyperarousal is the PTSD symptom cluster most tightly bound to widespread pain in young adults, then treatments that specifically dial down physiological arousal become attractive candidates for integrated care. Trauma-focused therapies that address arousal and reactivity, alongside interventions with demonstrated effects on both PTSD and pain, such as cognitive behavioral approaches, mindfulness-based stress reduction, and emotional awareness and expression therapy, could be sequenced or combined in ways that target the shared mechanism rather than treating the mind and the body as separate problems. The study’s authors suggest that hyperarousal may serve as a potential intervention target for the treatment of multi-region pain, a framing that could reshape how pain clinics screen their patients. A simple PTSD symptom checklist administered at intake might identify the young patients whose pain is most likely to be widespread and most likely to resist purely physical treatment.

The timing of this work is significant for another reason. Chronic pain affects a substantial share of young adults, and rates of PTSD symptoms among college students have been climbing in recent years, making the intersection of these two conditions a growing public health concern at a life stage when educational, vocational, and social trajectories are still being set. Prior research has linked multi-region pain to greater disease burden than localized pain, and studies in veterans and other trauma-exposed populations have reported similar associations between PTSD symptom clusters and multisite pain. What this study adds is a developmental window: evidence that even in early adulthood, before decades of pain chronicity accumulate, the arousal component of traumatic stress is already entangled with how far pain travels through the body. The sample is modest and cross-sectional, and the authors themselves frame their results as a call for longitudinal follow-up rather than a final verdict. But the message for researchers and clinicians alike is hard to ignore. When pain spreads, the nervous system’s threat-detection machinery may be spreading it, and calming that machinery could be one of the most direct routes to relief.

Subject of Research: The association between PTSD symptom clusters, particularly hyperarousal, and multi-region chronic pain in young adults

Article Title: Associations between PTSD symptom clusters and multi-region pain in young adults with chronic pain

Article References: Laumann, L. E., Gnall, K. E., Emrich, M., Sinnott, S. M., Powers, J. M., Stroud, L. R., & Cruess, D. G. (2026). Associations between PTSD symptom clusters and multi-region pain in young adults with chronic pain. Journal of Behavioral Medicine. https://doi.org/10.1007/s10865-026-00714-x

Image Credits: AI Generated

DOI: 10.1007/s10865-026-00714-x

Keywords: chronic pain, PTSD, hyperarousal, multi-region pain, young adults, central sensitization, pain interference, Michigan Body Map, trauma, sleep disturbance, Journal of Behavioral Medicine, logistic regression

The article opens with a composite scenario that will feel familiar to many rheumatologists. A 40-year-old woman is referred for possible lupus after endorsing diffuse joint and muscle pain, headaches, fatigue, dry eyes and mouth, gastrointestinal distress, cognitive fog, and non-restorative sleep on a standardized review of systems. Her physical examination is entirely unremarkable: no synovitis, rash, ulcers, alopecia, edema, or neurologic deficits. Her antinuclear antibody titer is 1:160 with a dense fine speckled pattern, but antibodies to extractable nuclear antigens and double-stranded DNA are negative, complement levels are normal, and inflammatory markers are not elevated. Despite never meeting classification criteria for systemic lupus erythematosus, she carries the diagnosis in her record, has received hydroxychloroquine and repeated courses of glucocorticoids for flares, and has been counseled to delay pregnancy because of supposed disease activity. Years later, the label persists even after the medication is stopped for lack of benefit, and she has never been evaluated for or educated about fibromyalgia.

Chatterjee traces part of the problem to how modern medicine documents symptoms. Evaluation and Management guidelines introduced by the Centers for Medicare and Medicaid Services in 1995 and 1997 incentivized exhaustive checklist documentation over concise diagnostic synthesis, a shift the American College of Physicians later criticized for embedding clinically uninformative phrases such as a negative 10-point review of systems into routine notes purely to satisfy billing requirements. Within this environment of note bloat, the review of systems evolved from a focused diagnostic tool into an indiscriminate symptom inventory that can escalate concern for autoimmune disease. Yet autoimmune rheumatic diseases rarely announce themselves through diffuse symptom accumulation alone. Accurate diagnosis depends on coherent clinical phenotypes built from objective findings, such as clinical synovitis, characteristic rashes, Raynaud phenomenon, serositis, cytopenias, glomerulonephritis, inflammatory myopathy, or biopsy-proven organ involvement, accompanied by disease-specific autoantibodies.

The statistical core of the argument is Bayesian. Systemic autoimmune rheumatic diseases are collectively uncommon in the general population, whereas fibromyalgia and related central sensitization syndromes affect roughly 2 to 4 percent of adults. In a low-prevalence setting, the pretest probability of autoimmune disease is low even among highly symptomatic patients, and adding more non-specific findings does little to move it. Fatigue, diffuse pain, sleep disturbance, paresthesias, and cognitive complaints are intentionally sensitive but weakly specific symptoms that occur frequently in the absence of autoimmune disease, so each additional low-specificity finding contributes negligible diagnostic information and may obscure meaningful signals. By contrast, objective inflammatory and organ-specific findings substantially increase post-test probability. Failing to account for these base rates, the author contends, predictably produces diagnostic error.

Several well-described cognitive biases amplify the problem. Availability bias raises suspicion for autoimmune disease because these conditions are memorable, complex, and emphasized during training. Base-rate neglect leads clinicians to overestimate the likelihood of rare diseases. Anchoring bias occurs when an early finding, particularly a positive antinuclear antibody, dominates subsequent reasoning even as contradictory evidence accumulates. Once an autoimmune label is introduced, diagnostic momentum sustains it: subsequent clinicians inherit the diagnosis, interpret new symptoms through that lens, and hesitate to reverse course. Electronic health records and templated documentation perpetuate diagnoses long after their evidentiary basis has eroded, with problem-list clutter and indiscriminate review-of-systems templates reinforcing the appearance of chronic multisystem disease. The author also acknowledges that these errors are psychologically compelling, because both clinicians and patients often seek explanations proportional to the magnitude of suffering, and a multisystem autoimmune label can feel validating even when it is inaccurate.

Antinuclear antibody testing illustrates how bias and inappropriate test utilization intersect. Although the test is highly sensitive across autoimmune rheumatic diseases, it lacks specificity and performs poorly as a screening tool in low-prevalence populations. Low-titer antinuclear antibody, at 1:80 or below by indirect immunofluorescence, is present in 14 to 25 percent of healthy individuals and 10 to 12 percent of patients with fibromyalgia. Outside appropriate clinical contexts, the positive predictive value of the test for lupus is often in the single digits. When testing is ordered in low-probability settings, a positive result frequently triggers cascades of additional serologic work, incidental abnormalities, patient anxiety, and provisional labels such as possible lupus or undifferentiated connective tissue disease. Autoantibodies alone do not establish causality and may coexist with symptoms arising from entirely different processes. The test does retain real utility through its high negative predictive value, approaching 98 percent for excluding lupus, reflecting sensitivity of roughly 95 percent for systemic lupus erythematosus and systemic sclerosis and 85 to 90 percent for Sjögren syndrome and mixed connective tissue disease.

Central sensitization syndromes complicate this picture because they produce real, often disabling symptoms without consistent structural or inflammatory correlates. The absence of a definitive biomarker can create discomfort around diagnostic uncertainty, prompting clinicians to substitute non-specific serologic abnormalities as explanatory anchors. Chatterjee argues that diagnosing fibromyalgia should be viewed not as diagnostic failure but as a conclusion grounded in probability, pattern recognition, and outcome-based evidence, and that recognizing symptom amplification rather than inflammation is a learned clinical skill requiring deliberate teaching. Social determinants of health, including chronic stress, early-life adversity, repetitive occupational strain, nutritional deficiencies, and socioeconomic disadvantage, can amplify pain processing and produce diffuse symptoms resembling fibromyalgia, broadening diagnostic reasoning beyond autoimmune paradigms. Fibromyalgia also commonly coexists with confirmed autoimmune disease, occurring in about 25 percent of rheumatoid arthritis, 30 percent of lupus, and up to 50 percent of primary Sjögren’s syndrome cases, where its symptom burden can be mistaken for inflammatory flare.

Fear of missing early lupus often drives ongoing surveillance, but longitudinal data are reassuring. In patients with fibromyalgia, including those with positive antinuclear antibodies, the risk of developing lupus is approximately 0.0027 percent per year, similar to the general population, and low-titer antinuclear antibody does not predict future autoimmune rheumatic disease. Among antibody-positive individuals without established disease, progression is uncommon and is driven by evolving objective clinical features, disease-specific autoantibodies, and interferon signatures rather than antibody positivity alone. Serial autoantibody testing adds little value in the absence of new clinical findings. The author notes that some diseases, including the spondyloarthritis spectrum, polymyalgia rheumatica, large- and medium-vessel vasculitis, and Still’s disease, are seronegative, so diagnosis in early or atypical presentations requires longitudinal reassessment rather than point-in-time evaluation.

The harms of misdiagnosis are not benign. Patients labeled with autoimmune disease may face prolonged anxiety, repeated testing, unnecessary referrals, and exposure to glucocorticoids, hydroxychloroquine, biologics, and other immunosuppressants that carry metabolic, skeletal, ophthalmologic, infectious, and financial risks without addressing the true driver of symptoms. Life decisions around pregnancy, employment, insurance, and identity may be altered, disproportionately affecting women. At the systems level, indiscriminate testing and referrals increase costs without improving outcomes. Clear communication is essential to the solution: framing fibromyalgia as a disorder of pain processing rather than tissue damage helps validate symptoms and explain the lack of response to immunosuppression, while diagnostic restraint should be presented as probability-based rather than inattentive. The article closes with principles for generalists, including reserving screening labs for targeted indications, refusing to let isolated low-titer results drive labeling, diagnosing functional disorders with validated criteria rather than by exclusion, and favoring longitudinal clinical assessment over serial laboratory testing. A pan-positive review of systems, the author concludes, should prompt diagnostic restraint rather than escalation, because precision in diagnosis requires resisting serologic noise and returning to reasoning grounded in probability, pattern recognition, and humility.

Subject of Research: Diagnostic anchoring on positive autoimmune serologies and its role in misdiagnosis of systemic autoimmune rheumatic disease in polysymptomatic patients

Article Title: Diagnostic Anchoring on Positive Autoimmune Serologies in Polysymptomatic Patients

Article References: Chatterjee, S. (2026). Diagnostic Anchoring on Positive Autoimmune Serologies in Polysymptomatic Patients. Journal of General Internal Medicine. https://doi.org/10.1007/s11606-026-10727-6

Image Credits: AI Generated

DOI: 10.1007/s11606-026-10727-6

Keywords: diagnostic anchoring, antinuclear antibody, autoimmune serologies, base-rate neglect, fibromyalgia, central sensitization, systemic lupus erythematosus, misdiagnosis, iatrogenic harm, overdiagnosis, rheumatology, low-value care